July 15, 2019
1 min read

Survival advantage suggested in responders to immunotherapy for uveal melanoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A possible survival advantage in patients with metastatic uveal melanoma who respond to treatment with pembrolizumab is suggested in a study of the anti-PD-1 monoclonal antibody as immunotherapy for advanced disease.

Researchers enrolled 17 patients with metastatic uveal melanoma in a prospective observational cohort single-arm study to investigate efficacy and safety of pembrolizumab as a first line-therapy. Endpoints were progression-free survival, complete or partial response or disease stabilization, clinical benefit, overall survival and tolerability.

A median of eight cycles of intravenous 2 mg/kg pembrolizumab every 3 weeks was administered. Range of administration cycles was two to 28, until disease progression, toxicity or withdrawal of consent. Toxicity was reported to be mild.

Two patients achieved a partial response and were without progression after 19.4 and 28.9 months (response rate, 11.7%). Both patients were still on treatment at the time of data analysis. Disease stabilized in six patients and progressed in nine. Eight of the 17 patients (47%) were deemed to have achieved clinical benefit.

Progression-free survival was 3.8 months for all patients, 9.7 months for patients whose interval between diagnosis of primary tumor to metastatic disease was longer than 5 years, and 2.6 months for patients whose same interval was less than 5 years.

“Based on our data, relapse after 5 years from the diagnosis of primary tumor could be considered a parameter to select patients who may benefit more from immunotherapy,” the authors said. “[T]he identification of predictive factors for response is crucial.” – by Robert Linnehan

Disclosures: The authors report no relevant financial disclosures.